C07J71/0047

Highly potent glucocorticoids

The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.

Glycyrrhetic acid derivatives

The glycyrrhetic acid derivatives can include: ##STR00001##
The glycyrrhetic acid derivatives can be used to treat inflammation and/or ulcers.

FUSED TRITERPENE COMPOUNDS AND USES THEREOF

The present invention discloses fused triterpene compounds, represented by the compounds of Formula I (as described herein), processes for their preparation, pharmaceutical compositions comprising the said compounds, their use as retinoid-related orphan receptors gamma (ROR) modulators and/or interleukin-17 (IL-17) inhibitors and methods for their use in the treatment of a disease or a disorder mediated by ROR and/or IL-17.

CHAGA MUSHROOM-RELATED FORMULATIONS, CHEMICAL COMPOUNDS, AND METHODS OF PRODUCTION AND USE THEREOF
20250268965 · 2025-08-28 ·

Medicinal and nutraceutical formulations based on Chaga mushrooms, chemical compounds and pharmaceutical compositions, and methods of production. When administered to a human or animal, the formulations, compounds, and pharmaceutical compositions are useful for the treatment of diseases such as cancers. The nutraceutical formulation includes a reduction of Chaga mushroom, where the reduction is formed in a reduction solvent; and an extraction of Chaga mushroom, where the extraction is formed in an extraction solvent. The reduction and extraction are mixed together or combined in accordance with methods known to those skilled in the art, to form the nutraceutical formulation. The medicinal formulation is a reaction product made by preparing a Chaga mushroom reduction in a reduction solvent under pressure, preparing a Chaga mushroom extraction in an extraction solvent, mixing or combining the Chaga reduction with the Chaga extraction, mixing or combining the Chaga formulation with an esterification mixture containing proline, fructose, and a fatty acid for the development of esterified compounds, and including sources of sugar esters capable of emulsion within otherwise non-miscible liquid compounds, or a predetermined amount of Manuka honey sufficient to cause esterification and facilitate emulsion at a temperature capable of inducing a reaction between the constituents of the Chaga mushroom with the constituents of the esterification mixture or Manuka honey, and combining that heterogenous mixture with medium chain triglyceride oil.